At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 769 enrolled
Drug / intervention
Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) +1 morebiological
Likely dose
Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose
In Brief
A Phase 4 clinical trial evaluating Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) for Pertussis and 2 related conditions. Completed, enrolled 769 participants across 7 sites.
Detailed Summary
The purpose of this study is to collect additional immunogenicity and safety data on re-dosing with Tdap vaccine (ADACEL®) in a continuing effort to address the public health need to establish broader population immunity against pertussis, as well as diphtheria and tetanus. Primary Objective: * To assess immune response to Tdap vaccine (ADACEL®) one month after booster vaccination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPertussis, Tetanus, Diphtheria
CountriesCanada
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJul 2008
Primary CompletionSep 2009
Study CompletionDec 2009
TodayJul 2026
First PostedJul 10, 2008
Enrollment StartJun 1, 2008
Primary CompletionSep 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.0 years ago
Interventions
Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)biological
0.5 ml, IM
Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)biological
0.5 mL, IM